Drug strategy of treatment of neuropathic pain syndrome in radiculopathy | Ukrainian Medical Journal

Osadchy O.I.

Main
Publications
Drug strategy of treatment of neuropathic pain syndrome in radiculopathy

Drug strategy of treatment of neuropathic pain syndrome in radiculopathy

November 9, 2018

994

Neurology and Psychiatry

Therapy, General practice

Osadchy O.I.

Specialities :

Neurology and Psychiatry

Therapy, General practice

Resume

Actuality of problem of radiculopathy is shown in the review. Epidemiology data, reasons, mechanisms of development, clinical presentation and methods of drug treatment of neuropathic pain in radiculopathy are presented. Recommendations of the international organizations for the treatment of the pain are given. Efficiency and safety of gebapenthinoides are described, including pregabalin, as the drug of the last generation, recommended for treatment of neuropathic pain. Its clinical efficiency in treatment of neuropathic pain syndrome was studied in a number of clinical randomized researches, showing its analgetic action and also ability to cause regress of concomitant psychosomatic disorders and insomnia in patients with lumbosacral neuropathy.

Key words: chronic pain, back pain, neuropathic pain, nociceptive pain, gebapenthinoides, pregabalin, radiculopathy.

Published: 09.11.2018

References:

Vorobeva O. (2014) Konservativnoe lechenie poyasnichno-kresttsovoy radikulyarnoy boli. Vrach, 9: 8–11.
Danilov A.B., Danilov A.B. (2013) Biopsihosotsiokulturnaya model i hronicheskaya bol. Sovrem. ter. psih. nevrol., 1: 30–36.
Kryizhanovskiy G.N. (2001) Tsentralnyie patofiziologicheskie mehanizmyi patologicheskoy boli. Nauch.-prakt. konf. s mezhdunar. uchastiem «Klinicheskie i teoreticheskie aspektyi boli». Moskva, 14 s.
Andre V., Rigoulot M.A., Koning E. (2003) Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia, 44: 893–903.
Attal N., Cruccu G., Baron R. et al. (2010) European Federation of Neurological Societies: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol., 17: e1113–e1188.
Attal N., Cruccu G., Haanpaa M. et al. (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol., 13: 1153–1169.
Attal N., Fermanian C., Fermanian J. et al. (2008) Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain, 138(2): 343–353.
Attal N., Lanteri-Minet M., Laurent B. et al. (2011) The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain, 152: 2836–2843.
Baron R., Freynhagen R., Tölle T.R. et al. (2010) The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain, 150(3): 420–427 (doi: 10.1016/j.pain.2010.04.013).
Berger A., Dukes E.M., Oster G. (2004) Clinical characteristics and economic costs of patients with painful neuropathic disorders. J. Pain, 5: 143–149.
Centre for Clinical Practice at NICE (UK) (2010) Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. London: National Institute for Health and Clinical Excellence (UK).
Colloca L., Ludman T., Bouhassira D. et al. (2017) Neuropathic pain. Nat. Rev. Dis. Primers, 3: 17002.
Eccleston C., Hearn L., Williams A.C. (2015) Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 10: CD011259.
Field M.J., Li Z.,Schwarz J.B. (2007) Ca²⁺ channel alpha2-delta ligands for the treatment of neuropathic pain. J. Med Chem., 50(11): 2569–2575.
Finnerup N.B., Haroutounian S., Kamerman P. et al. (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain, 157(8): 1599–1606.
Finnerup N.B., Otto M., McQuay H.J. et al. (2005) Algorithm for neuropathic pain treatment — an evidence based proposal Pain, 118(3): 289–305.
Freynhagen R., Baron R. (2009) The evaluation of neuropathic components in low back pain Curr. Pain Headache Rep., 13(3): 185–190.
Freynhagen R., Baron R., Tölle T. et al. (2006) Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT) Curr. Med. Res. Opin., 22: 529–537.
Freynhagen R., Strojek K., Griesing T. et al. (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of fable- and fixed-dose regimens. Pain, 115(3): 254–263.
Gore M., Dukes E., Rowbotham D.J. et al. (2007) Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur. J. Pain, 11(6): 652–664.
Hurley R.W., Chatterjea D., Rose F.M. et al. (2002) Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology, 97: 1263–1273.
Johnson E.W., Fletcher F.R. (1981) Lumbosacral radiculopathy: review of 100 consecutive cases. Arch. Phys. Med. Rehabil., 62(7): 321–323.
Knight T., Schaefer C., Chandran A. et al. (2013) Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon. Outcomes Res., 5: 171–180.
Martinez V., Attal N., Bouhassira D. et al. (2010) Chronic neuropathic pain: diagnosis, evaluation and treatment in outpatient services. Guidelines for clinical practice of the French Society for the Study and Treatment of Pain. Douleur analg., 23: 51–66.
Martinez V., Attal N., Vanzo B. et al. (2014) Adherence of French GPs to chronic neuropathic pain clinical guidelines: results of a cross-sectional, randomized, «e» case-vignette survey. PLoS One, 9(4): e93855.
Moulin D.E., Clark A.J., Gilron I. et al. (2007) Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res. Manag., 12(1): 13–21.
Orita S., Yamashita M., Eguchi Y. et al. (2016) Pregabalin for Refractory Radicular Leg Pain due to Lumbar Spinal Stenosis: A Preliminary Prospective Study. Pain Res. Manag. (https://www.hindawi.com/journals/prm/2016/5079675/).
Pérez C., Navarro A., Saldaña M.T. et al. (2013) Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain. Pain Med., 14(12): 1954–1963.
Radat F., Margot-Duclot A., Attal N. (2013) Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study. Eur. J. Pain, 17(10): 1547–1557.
Taguchi T., Igarashi A., Watt S. et al. (2015) Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan. J. Pain Res., 8: 487–497.
Tesfaye S., Boulton A.J., Dickenson A.H. et al. (2013) Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care, 36: 2456–2465.
Tolle T., Dukes E., Sadosky A. et al. (2006) Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract., 6(3): 153–160.
Toth C. (2014) Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther. Adv. Drug Saf., 5(1): 38–56.
Woolf C.J., Bennett G.J., Doherty M. et al. (1998) Towards a mechanism-based classification of pain? Pain, 77(3): 227–229.
Yamashita T., Takahashi K., Yonenobu K. et al. (2014) Prevalence of neuropathic pain in cases with chronic pain related to spinal disorders. J. Orthop. Scien., 19(1): 15–21.
Yarnitsky D. (2015) Role of endogenous pain modulation in chronic pain mechanisms and treatment. Pain, 156: S24–S31.